Biosimilars – Market Events And Forecast – Endocrinology
In 2020, sales of insulins at the ex-manufacturer price level exceeded $11 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2020-2030 forecast period, the originator insulins manufactured by Eli Lilly, Novo Nordisk, and Sanofi will face increasing competition from insulin biosimilars / follow-on insulins, eroding both patient share and drug prices. We present our forecasts for key reference brand insulins and their biosimilars / follow-on insulins by therapeutic area, molecule, and country / region.
Table of contents
- Biosimilars - Market Events And Forecast - Endocrinology
- Market Forecast in the Major Pharmaceutical Markets
- Major-Market Forecast: Endocrinology Biologics (Insulin Analogues)
- Terminology
- Overarching Forecast Assumptions
- Overview of Insulin Brands in Forecast
- Overview of Approved Insulins
- Biosimilar Entry Assumptions for Approved Insulins
- Overview of Insulin Biosimilar Assumptions
- Overview of Insulin Brands in Forecast
- Drug-Specific Forecast Assumptions
- Lantus
- Outlook for Lantus
- First Major-Market Biosimilar Entrants
- Order of Entry in the United States
- Order of Entry in the EU5
- Order of Entry in Japan
- Biosimilar Uptake Assumptions
- Biosimilar and Brand Ex-Manufacturing Price Assumptions
- Lantus Sales Forecast in the United States: 2020-2030
- Lantus Sales Forecast in the EU5: 2020-2030
- Lantus Sales Forecast in Japan: 2020-2030
- Levemir
- Outlook for Levemir
- First Major-Market Biosimilar Entrants
- Biosimilar Uptake Assumptions
- Biosimilar and Brand Ex-Manufacturing Price Assumptions
- Levemir Sales Forecast in the United States: 2020-2030
- Levemir Sales Forecast in the EU5: 2020-2030
- Levemir Sales Forecast in Japan: 2020-2030
- Humalog / Humalog Mix
- Outlook for Humalog / Humalog Mix
- First Major-Market Biosimilar Entrants
- Order of Entry in the United States
- Order of Entry in the EU5
- Order of Entry in Japan
- Biosimilar Uptake Assumptions
- Biosimilar and Brand Ex-Manufacturing Price Assumptions
- Humalog / Humalog Mix Sales Forecast in the United States: 2020-2030
- Humalog / Humalog Mix Sales Forecast in the EU5: 2020-2030
- Humalog / Humalog Mix Sales Forecast in Japan: 2020-2030
- NovoLog / NovoRapid and NovoMix
- Outlook for NovoLog / NovoRapid and NovoMix
- First Major-Market Biosimilar Entrants (NovoLog and NovoRapid)
- First Major-Market Biosimilar Entrants (NovoMix)
- Biosimilar Uptake Assumptions
- Biosimilar and Brand Ex-Manufacturing Price Assumptions
- NovoLog / NovoRapid Sales Forecast in the United States: 2020-2030
- NovoLog / NovoRapid Sales Forecast in the EU5: 2020-2030
- NovoLog / NovoRapid Sales Forecast in Japan: 2020-2030
- NovoMix Sales Forecast in the United States: 2020-2030
- NovoMix Sales Forecast in the EU5: 2020-2030
- NovoMix Sales Forecast in Japan: 2020-2030
- Lantus
- Market Forecast in the Major Pharmaceutical Markets
Hamzah Aideed, M.Sc., is a manager on the Biosimilars team at Clarivate. His team conducts both primary and secondary market research to provide in-depth analysis and key insights into biosimilars and the biopharmaceutical industry. Previously, Mr. Aideed was a senior research executive in consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies for bespoke ad-hoc consulting projects. He holds an M.Sc. in biotechnology, bioprocessing, and business management from the University of Warwick and a B.Sc. in biological chemistry from Aston University in Birmingham.
Anushree Dhar, M.Sc., is an analyst on the Biosimilars team at Clarivate. She has several years of experience working in competitive intelligence, medical, and pharmaceutical syndicated research. Prior to joining Clarivate, she was a senior consultant at TheraTraQ, where she was involved in biosimilar and CNS projects for global pharmaceutical clients. Ms. Dhar also worked as an industry analyst at Technavio, part of Infiniti Research, where she worked on various syndicated research reports, conducted primary and secondary research, and prepared reports on clinical trials. Ms. Dhar earned her M.Sc. degree in biotechnology at Bangalore University.